The effect of adjunctive armodafinil on cognitive performance and psychopathology in antipsychotic-treated patients with schizophrenia/schizoaffective disorder: A randomized, double-blind, placebo-controlled trial

Schizophrenia Research

Volumn 130, Issue 1-3, 2011, Pages 106-113

  Bobo, William V ^a   Woodward, Neil D ^a   Sim, Min Young ^b   Jayathilake, Karuna ^a   Meltzer, Herbert Y ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Seoul National University Hospital   (South Korea)

Author keywords

Adjunctive treatment; Armodafinil; Depressive symptoms; Negative symptoms; Neurocognition; Schizophrenia

Indexed keywords

ARIPIPRAZOLE; ARMODAFINIL; CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ADJUVANT THERAPY; ADULT; AKATHISIA; ALERTNESS; ANHEDONIA; ANTISOCIAL BEHAVIOR; ARTICLE; ATTENTION; AUDITORY HALLUCINATION; COGNITION; CONSTIPATION; CONTROLLED STUDY; DEPRESSION; DIAPHORESIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSTONIA; EJACULATION DISORDER; ERECTILE DYSFUNCTION; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HEART PALPITATION; HUMAN; HYPOKINESIA; LIBIDO DISORDER; MAJOR CLINICAL STUDY; MALE; MENTAL PERFORMANCE; MORNING DOSAGE; MUSCLE RIGIDITY; NEGATIVE SYNDROME; NEUROPSYCHOLOGICAL TEST; ORGASM DISORDER; ORTHOSTATIC INTOLERANCE; POSITIVE SYNDROME; PRIORITY JOURNAL; PSYCHOLOGICAL RATING SCALE; RANDOMIZED CONTROLLED TRIAL; SCALE FOR THE ASSESSMENT OF NEGATIVE SYMPTOMS; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SEXUAL DYSFUNCTION; SIDE EFFECT; SLEEP DISORDER; TACHYCARDIA; TREMOR; WAKEFULNESS;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; BENZHYDRYL COMPOUNDS; COGNITION DISORDERS; DOUBLE-BLIND METHOD; FACTOR ANALYSIS, STATISTICAL; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PSYCHIATRIC STATUS RATING SCALES; PSYCHOPATHOLOGY; PSYCHOTIC DISORDERS; RETROSPECTIVE STUDIES; SCHIZOPHRENIA; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79960315525     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2011.05.015     Document Type: Article

References (57)

1. Addington D., Addington J., Maticka-Tyndale E. Assessing depression in schizophrenia: the Calgary Depression Scale. Br. J. Psychiatry 1993, (Suppl. 39-44).
2. Andreasen N.C. The Scale for the Assessment of Negative Symptoms (SANS): conceptual and theoretical foundations. Br. J. Psychiatry 1989, (Suppl. 49-58).
3. Barch D.M., Carter C.S. Measurement issues in the use of Cognitive Neuroscience Tasks in Drug Development for Impaired Cognition in Schizophrenia: a report of the second consensus building conference of the CNTRICS initiative. Schizophr. Bull. 2008, 34:613-618. CNTRICS Executive Committee.
4. Barnes T.R. A rating scale for drug-induced akathisia. Br. J. Psychiatry 1989, 154:672-676.
5. Bowie C.R., Harvey P.D. Cognition in schizophrenia: impairments, determinants, and functional importance. Psychiatr. Clin. North Am. 2005, 28(613-33):626.
6. Calabrese J.R., Ketter T.A., Youakim J.M., Tiller J.M., Yang R., Frye M.A. Adjunctive armodafinil for major depressive episodes associated with bipolar I disorder: a randomized, multicenter, double-blind, placebo-controlled, proof-of-concept study. J. Clin. Psychiatry 2010, 71:1363-1370.
7. Carter C.S., Barch D.M., Buchanan R.W., Bullmore E., Krystal J.H., Cohen J., Geyer M., Green M., Neuchterlein K.H., Robbins T., Silverstein S., Smith E.E., Strauss M., Wykes T., Heinssen R. Identifying cognitive mechanisms targeted for treatment development in schizophrenia: an overview of the first meeting of the Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia initiative. Biol. Psychiatry 2008, 64:4-10.
8. Citrome L., Levine J., Allingham B. Changes in use of valproate and other mood stabilizers for patients with schizophrenia from 1994 to 1998. Psychiatr. Serv. 2000, 51:634-638.
9. Clinical Global Impressions ECDEU Assessment Manual for Psychopharmacology, Revised (DHEW Publ No ADM 76-338) 1976, 218-222. National Institute of Mental Health, Rockville, MD, Ref Type: Generic.
10. Darwish M., Kirby M., Hellriegel E.T., Robertson P. Armodafinil and modafinil have substantially different pharmacokinetic profiles despite having the same terminal half-lives: analysis of data from three randomized, single-dose, pharmacokinetic studies. Clin. Drug Investig. 2009, 29:613-623.
11. DeBattista C., Lembke A., Solvason H.B., Ghebremichael R., Poirier J. A prospective trial of modafinil as an adjunctive treatment of major depression. J. Clin. Psychopharmacol. 2004, 24:87-90.
12. Dinges D.F., Arora S., Darwish M., Niebler G.E. Pharmacodynamic effects on alertness of single doses of armodafinil in healthy subjects during a nocturnal period of acute sleep loss. Curr. Med. Res. Opin. 2006, 22:159-167.
13. Floresco S.B., Magyar O. Mesocortical dopamine modulation of executive functions: beyond working memory. Psychopharmacology (Berl) 2006, 188:567-585.
14. Freudenreich O., Henderson D.C., Macklin E.A., Evins A.E., Fan X., Cather C., Walsh J.P., Goff D.C. Modafinil for clozapine-treated schizophrenia patients: a double-blind, placebo-controlled pilot trial. J. Clin. Psychiatry 2009, 70:1674-1680.
15. Frye M.A., Grunze H., Suppes T., McElroy S.L., Keck P.E., Walden J., Leverich G.S., Altshuler L.L., Nakelsky S., Hwang S., Mintz J., Post R.M. A placebo-controlled evaluation of adjunctive modafinil in the treatment of bipolar depression. Am. J. Psychiatry 2007, 164:1242-1249.
16. Ganguly R., Kotzan J.A., Miller S., Kennedy K., Martin B.C. Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000. J. Clin. Psychiatry 2004, 65:1377-1388.
17. Harsh J.R., Hayduk R., Rosenberg R., Wesnes K.A., Walsh J.K., Arora S., Niebler G.E., Roth T. The efficacy and safety of armodafinil as treatment for adults with excessive sleepiness associated with narcolepsy. Curr. Med. Res. Opin. 2006, 22:761-774.
18. Hart C.L., Haney M., Vosburg S.K., Comer S.D., Gunderson E., Foltin R.W. Modafinil attenuates disruptions in cognitive performance during simulated night-shift work. Neuropsychopharmacology 2006, 31:1526-1536.
19. Harvey P.D., Keefe R.S. Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am. J. Psychiatry 2001, 158:176-184.
20. Hirshkowitz M., Black J.E., Wesnes K., Niebler G., Arora S., Roth T. Adjunct armodafinil improves wakefulness and memory in obstructive sleep apnea/hypopnea syndrome. Respir. Med. 2007, 101:616-627.
21. Hunter M.D., Ganesan V., Wilkinson I.D., Spence S.A. Impact of modafinil on prefrontal executive function in schizophrenia. Am. J. Psychiatry 2006, 163:2184-2186.
22. Ichikawa J., Ishii H., Bonaccorso S., Fowler W.L., O'Laughlin I.A., Meltzer H.Y. 5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J. Neurochem. 2001, 76:1521-1531.
23. Johns M.W. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 1991, 14:540-545.
24. Kane J.M., D'Souza D.C., Patkar A.A., Youakim J.M., Tiller J.M., Yang R., Keefe R.S. Armodafinil as adjunctive therapy in adults with cognitive deficits associated with schizophrenia: a 4-week, double-blind, placebo-controlled study. J. Clin. Psychiatry 2010, 71:1475-1481.
25. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13:261-276.
26. Keefe R.S., Bilder R.M., Davis S.M., Harvey P.D., Palmer B.W., Gold J.M., Meltzer H.Y., Green M.F., Capuano G., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., Davis C.E., Hsiao J.K., Lieberman J.A. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch. Gen. Psychiatry 2007, 64:633-647.
27. Keefe R.S., Sweeney J.A., Gu H., Hamer R.M., Perkins D.O., McEvoy J.P., Lieberman J.A. Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison. Am. J. Psychiatry 2007, 164:1061-1071.
28. Krupp L.B., LaRocca N.G., Muir-Nash J., Steinberg A.D. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch. Neurol. 1989, 46:1121-1123.
29. Lane R.D., Glazer W.M., Hansen T.E., Berman W.H., Kramer S.I. Assessment of tardive dyskinesia using the Abnormal Involuntary Movement Scale. J. Nerv. Ment. Dis. 1985, 173:353-357.
30. Liegeois J.F., Ichikawa J., Meltzer H.Y. 5-HT(2A) receptor antagonism potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and inhibits that in the nucleus accumbens in a dose-dependent manner. Brain Res. 2002, 947:157-165.
31. Lingjaerde O., Ahlfors U.G., Bech P., Dencker S.J., Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr. Scand. 1987, (Suppl. 334):1-100.
32. Luborzewski A., Regen F., Schindler F., Anghelescu I. Modafinil-induced reversible hyperkinetic nondystonic movement disorder in a patient with major depressive disorder. J. Neuropsychiatry Clin. Neurosci. 2006, 18:248-249.
33. Maser R.V., Liao B., Pandya R. Modafinil-induced orofacial dyskinesia in an elderly patient with refractory bipolar depression. J. Neuropsychiatry Clin. Neurosci. 2010, 22:E26.
34. Minzenberg M.J., Carter C.S. Modafinil: a review of neurochemical actions and effects on cognition. Neuropsychopharmacology 2008, 33:1477-1502.
35. Morein-Zamir S., Turner D.C., Sahakian B.J. A review of the effects of modafinil on cognition in schizophrenia. Schizophr. Bull. 2007, 33:1298-1306.
36. Narendran R., Young C.M., Valenti A.M., Nickolova M.K., Pristach C.A. Is psychosis exacerbated by modafinil?. Arch. Gen. Psychiatry 2002, 59:292-293.
37. Pedersen C.S., Goetghebeur P., Dias R. Chronic infusion of PCP via osmotic mini-pumps: a new rodent model of cognitive deficit in schizophrenia characterized by impaired attentional set-shifting (ID/ED) performance. J. Neurosci. Methods 2009, 185:66-69.
38. Pierre J.M., Peloian J.H., Wirshing D.A., Wirshing W.C., Marder S.R. A randomized, double-blind, placebo-controlled trial of modafinil for negative symptoms in schizophrenia. J. Clin. Psychiatry 2007, 68:705-710.
39. Robertson P., Hellriegel E.T. Clinical pharmacokinetic profile of modafinil. Clin. Pharmacokinet. 2003, 42:123-137.
40. Rosenthal M.H., Bryant S.L. Benefits of adjunct modafinil in an open-label, pilot study in patients with schizophrenia. Clin. Neuropharmacol. 2004, 27:38-43.
41. Roth T., Rippon G.A., Arora S. Armodafinil improves wakefulness and long-term episodic memory in nCPAP-adherent patients with excessive sleepiness associated with obstructive sleep apnea. Sleep Breath. 2008, 12:53-62.
42. Schwartz J.R., Nelson M.T., Schwartz E.R., Hughes R.J. Effects of modafinil on wakefulness and executive function in patients with narcolepsy experiencing late-day sleepiness. Clin. Neuropharmacol. 2004, 27:74-79.
43. Sevy S., Rosenthal M.H., Alvir J., Meyer S., Visweswaraiah H., Gunduz-Bruce H., Schooler N.R. Double-blind, placebo-controlled study of modafinil for fatigue and cognition in schizophrenia patients treated with psychotropic medications. J. Clin. Psychiatry 2005, 66:839-843.
44. Shuman T., Wood S.C., Anagnostaras S.G. Modafinil and memory: effects of modafinil on Morris water maze learning and Pavlovian fear conditioning. Behav. Neurosci. 2009, 123:257-266.
45. Simpson G.M., Angus J.W. A rating scale for extrapyramidal side effects. Acta Psychiatr. Scand. 1970, (Suppl. 212):11-19.
46. Spence S.A., Green R.D., Wilkinson I.D., Hunter M.D. Modafinil modulates anterior cingulate function in chronic schizophrenia. Br. J. Psychiatry 2005, 187:55-61.
47. Tapp A., Wood A.E., Secrest L. Combination antipsychotic therapy in clinical practice. Psychiatr. Serv. 2003, 54:55-59.
48. Turner D.C., Clark L., Dowson J., Robbins T.W., Sahakian B.J. Modafinil improves cognition and response inhibition in adult attention-deficit/hyperactivity disorder. Biol. Psychiatry 2004, 55:1031-1040.
49. Turner D.C., Clark L., Pomarol-Clotet E., McKenna P., Robbins T.W., Sahakian B.J. Modafinil improves cognition and attentional set shifting in patients with chronic schizophrenia. Neuropsychopharmacology 2004, 29:1363-1373.
50. Vytopil M., Mani R., Adlakha A., Zhu J.J. Acute chorea and hyperthermia after concurrent use of modafinil and tranylcypromine. Am. J. Psychiatry 2007, 164:684.
51. Walsh J.K., Randazzo A.C., Stone K.L., Schweitzer P.K. Modafinil improves alertness, vigilance, and executive function during simulated night shifts. Sleep 2004, 27:434-439.
52. Waters K.A., Burnham K.E., O'connor D., Dawson G.R., Dias R. Assessment of modafinil on attentional processes in a five-choice serial reaction time test in the rat. J. Psychopharmacol. 2005, 19:149-158.
53. Westerink B.H., Kawahara Y., De B.P., Geels C., De Vries J.B., Wikstrom H.V., Van K.A., Van V.B., Kruse C.G., Long S.K. Antipsychotic drugs classified by their effects on the release of dopamine and noradrenaline in the prefrontal cortex and striatum. Eur. J. Pharmacol. 2001, 412:127-138.
54. Wisor J.P., Dement W.C., Aimone L., Williams M., Bozyczko-Coyne D. Armodafinil, the R-enantiomer of modafinil: wake-promoting effects and pharmacokinetic profile in the rat. Pharmacol. Biochem. Behav. 2006, 85:492-499.
55. Wong Y.N., King S.P., Simcoe D., Gorman S., Laughton W., McCormick G.C., Grebow P. Open-label, single-dose pharmacokinetic study of modafinil tablets: influence of age and gender in normal subjects. J. Clin. Pharmacol. 1999, 39:281-288.
56. Wong Y.N., Simcoe D., Hartman L.N., Laughton W.B., King S.P., McCormick G.C., Grebow P.E. A double-blind, placebo-controlled, ascending-dose evaluation of the pharmacokinetics and tolerability of modafinil tablets in healthy male volunteers. J. Clin. Pharmacol. 1999, 39:30-40.
57. Woodward N.D., Purdon S.E., Meltzer H.Y., Zald D.H. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int. J. Neuropsychopharmacol. 2005, 8:457-472.